Breast Biopsy Device Market Is Projected To Reach $911.2 Million By 2024: Grand View Research, Inc.
The breast biopsy device market is expected to reach
USD 911.2 million by 2024, according to a new report by Grand View Research,
Inc. The Breast biopsy device market is projected to grow at a productive rate
in the next few years. The key factors supporting the industry’s growth involve
the rising awareness levels with regard to diagnostic procedures through cancer
screening programs, global rise in breast cancers in women, and the high demand
for less-invasive procedures. However, the degree of risk is directly
proportional to the extent of procedure invasiveness. Biopsy causes pain and is
a stressful procedure for patients, moreover, approximately 60% to 80% of
breast biopsies in women result in a benign judgment. Therefore, women are
encouraged to consult experts for a second opinion before undergoing a biopsy
procedure, which is likely to hinder the growth of the market.
The test type segment is
categorized into needle breast biopsies and open surgical biopsies. The former
is further segmented into fine-needle aspiration, core-needle, and
vacuum-assisted core biopsy. The fine-needle aspiration segment is estimated to
hold the largest share for the year 2015 whereas the vacuum-assisted core
biopsy segment is anticipated to witness a lucrative growth during the study
period. The open surgical biopsy industry is sub-segmented into Incisional
biopsy and Excisional biopsy.
On the basis of products, the
industry is categorized into needles, tables, localization wires, and guidance
systems. Additionally, the guidance systems segment of the industry is further
categorized on the basis of imaging systems, such as ultrasound, mammography,
and magnetic resonance imaging.
U.S. Breast Biopsy Device
Market, by guidance type, 2013 - 2024 (USD Million)
Browse full research report on
Breast
Biopsy Device Market
Further key findings from the
report suggest:
- The Asia
Pacific region is anticipated to witness the highest growth rate, with a
CAGR of around 12.6% during the forecast period. The high frequencies of
breast cancer prevailing in women as well as the increase in awareness of
cancer screening programs are the factors fueling the market growth.
- North America
accounts for the largest market share, followed by the European market.
The heightened awareness about breast cancer that advocate regular
checkups and screening programs along with the demand for accurate and
minimally caustic procedures are factors that are responsible for the
rapid market growth.
- The
mammography-guided stereotactic segment is estimated to hold the largest
market share followed by the magnetic resonance imaging-guided category.
The rise in demand for rapid and precise diagnostic imaging tools in
determining the exact location of the tumor or lump in the breast area is
one of the major factors driving the growth of this industry
- On the basis
of test type, the needle-based biopsy segment accounts for the largest
share; this is mainly due to the high demand for minimally invasive
procedures. On the other hand, the open surgical biopsies have a
probability to witness a decline in the market over the next few years due
to the relatively high invasiveness and the risks involved with the
procedure.
- Some major
players in this industry include Becton, Dickenson and Company (BD),C.R
Bard, Inc., Devicor medical, Inc., and Hologic, Inc., among others.
About Grand View Research,
Inc:
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For more information: http://www.grandviewresearch.com
Comments
Post a Comment